| Study characteristics |
| Methods |
Randomized controlled trial |
| Participants |
Adults (aged 18 to 65 years) with active ulcerative colitis (N = 135) |
| Interventions |
Olsalazine 3 g/day (n = 105) or SASP 4 g/day (n = 30) |
| Outcomes |
Clinical improvement and adverse events |
| Notes |
Funding support and conflicts of interest were not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not described |
| Selective reporting (reporting bias) |
Unclear risk |
Not described |
| Other bias |
Unclear risk |
Not described |
